S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$4.07
-1.2%
$5.02
$4.02
$10.45
$334.19M0.561.43 million shs1.33 million shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$382.44
-0.7%
$393.75
$185.43
$419.42
$11.85B1.38240,902 shs212,271 shs
National Research Co. stock logo
NRC
National Research
$33.32
-3.0%
$38.76
$33.25
$47.25
$794.68M0.4272,976 shs41,923 shs
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
+0.0%
$42.86
$22.89
$52.23
$4.46B1.581.92 million shs7.39 million shs
Zymergen Inc. stock logo
ZY
Zymergen
$2.43
$2.52
$1.10
$12.42
$253.58M1.691.23 million shs85 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-1.21%-5.13%-15.56%-32.28%-49.88%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-0.68%-3.84%-2.17%+31.19%+99.52%
National Research Co. stock logo
NRC
National Research
-3.03%-5.90%-16.22%-15.73%-24.00%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%+6.68%
Zymergen Inc. stock logo
ZY
Zymergen
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.2984 of 5 stars
3.50.00.04.72.81.70.0
Medpace Holdings, Inc. stock logo
MEDP
Medpace
4.4638 of 5 stars
1.44.00.04.62.74.23.1
National Research Co. stock logo
NRC
National Research
0.5638 of 5 stars
0.03.01.70.01.00.81.3
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.4802 of 5 stars
1.00.00.04.50.61.71.3
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.00
Buy$40.00882.80% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.75
Moderate Buy$382.00-0.12% Downside
National Research Co. stock logo
NRC
National Research
N/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
2.00
Hold$43.000.05% Upside
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/A

Current Analyst Ratings

Latest MEDP, SYNH, ZY, AVXL, and NRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$395.00
2/15/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$282.00 ➝ $452.00
2/14/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$312.00 ➝ $408.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.73 per shareN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$1.89B6.28$9.95 per share38.43$18.22 per share20.99
National Research Co. stock logo
NRC
National Research
$148.58M5.35$1.48 per share22.48$2.02 per share16.50
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27
Zymergen Inc. stock logo
ZY
Zymergen
$16.74M15.15N/AN/A$3.99 per share0.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$47.51M-$0.54N/AN/AN/AN/A-30.32%-27.87%5/14/2024 (Estimated)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$282.81M$8.8843.0730.042.0515.00%63.98%19.02%4/22/2024 (Confirmed)
National Research Co. stock logo
NRC
National Research
$30.97M$1.2526.66N/A20.84%47.79%24.27%5/7/2024 (Estimated)
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A
Zymergen Inc. stock logo
ZY
Zymergen
-$361.79M-$3.55N/AN/AN/A-2,508.94%-93.37%-61.14%N/A

Latest MEDP, SYNH, ZY, AVXL, and NRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/22/2024N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.45N/A-$2.45N/AN/AN/A  
2/13/2024Q4 2023
National Research Co. stock logo
NRC
National Research
N/A$0.36+$0.36$0.36N/A$38.00 million
2/12/202412/31/2023
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.22$2.46+$0.24$2.46$498.72 million$498.40 million    
2/7/2024Q1 2024
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.15-$0.11+$0.04-$0.11N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
National Research Co. stock logo
NRC
National Research
$0.481.44%+31.73%38.40%N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/AN/A

Latest MEDP, SYNH, ZY, AVXL, and NRC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2024
National Research Co. stock logo
NRC
National Research
Quarterly$0.121.2%3/27/20243/29/20244/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
11.85
11.85
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.64
0.64
National Research Co. stock logo
NRC
National Research
0.60
0.67
0.67
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20
Zymergen Inc. stock logo
ZY
Zymergen
N/A
4.59
4.47

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
National Research Co. stock logo
NRC
National Research
47.26%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
91.16%
Zymergen Inc. stock logo
ZY
Zymergen
52.99%

Insider Ownership

CompanyInsider Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.60%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.30%
National Research Co. stock logo
NRC
National Research
2.40%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.34%
Zymergen Inc. stock logo
ZY
Zymergen
11.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4082.11 million72.59 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
5,90030.98 million24.69 millionOptionable
National Research Co. stock logo
NRC
National Research
43523.85 million23.28 millionOptionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable
Zymergen Inc. stock logo
ZY
Zymergen
502104.36 million92.15 millionNot Optionable

MEDP, SYNH, ZY, AVXL, and NRC Headlines

SourceHeadline
Method Communications Introduces New Leadership Structure to Accelerate MomentumMethod Communications Introduces New Leadership Structure to Accelerate Momentum
finance.yahoo.com - April 10 at 10:51 AM
Ginkgo loads up CAR assets from Modulus, the latest in a string of dealsGinkgo loads up CAR assets from Modulus, the latest in a string of deals
fiercebiotech.com - April 2 at 8:57 AM
Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029
tmcnet.com - March 21 at 5:22 PM
GM puts 2 newcomers in pivotal rolesGM puts 2 newcomers in pivotal roles
autonews.com - March 15 at 1:53 PM
Transportation Transitions: Transervice, Fultra, and GM name new leadershipTransportation Transitions: Transervice, Fultra, and GM name new leadership
fleetowner.com - March 15 at 8:52 AM
Biotech Industry Bankruptcy Cases: Zymergen and HumanigenBiotech Industry Bankruptcy Cases: Zymergen and Humanigen
law.com - March 14 at 1:41 PM
GM EVP of global manufacturing and sustainability Gerald Johnson to retire after 44 YearsGM EVP of global manufacturing and sustainability Gerald Johnson to retire after 44 Years
auto.economictimes.indiatimes.com - March 14 at 2:18 AM
GM Appoints Former Tesla and Google Executive to Succeed Retiring Head of ManufacturingGM Appoints Former Tesla and Google Executive to Succeed Retiring Head of Manufacturing
msn.com - March 13 at 8:08 PM
GM Taps Former Tesla Gigafactory Head To Lead ManufacturingGM Taps Former Tesla Gigafactory Head To Lead Manufacturing
marketwatch.com - March 13 at 10:08 AM
GM announces a management shakeup as it loses 2 key executivesGM announces a management shakeup as it loses 2 key executives
freep.com - March 12 at 6:06 PM
GM hires ex-Tesla, Google exec to replace retiring head of manufacturingGM hires ex-Tesla, Google exec to replace retiring head of manufacturing
nbcnewyork.com - March 12 at 6:06 PM
Q4 2023 Ginkgo Bioworks Holdings Inc Earnings CallQ4 2023 Ginkgo Bioworks Holdings Inc Earnings Call
finance.yahoo.com - March 1 at 2:42 PM
Project Izanagi: Masayoshi Son plans $100bn AI chip ventureProject Izanagi: Masayoshi Son plans $100bn AI chip venture
datacenterdynamics.com - February 18 at 10:15 AM
MATTERWORKS ANNOUNCES BOARD UPDATESMATTERWORKS ANNOUNCES BOARD UPDATES
finance.yahoo.com - February 13 at 2:16 AM
SmartLabs gets $48M investment; CEO says we’re not doneSmartLabs gets $48M investment; CEO says 'we’re not done'
bizjournals.com - January 19 at 9:53 AM
SmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEOSmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEO
finance.yahoo.com - January 11 at 7:19 AM
Adam D’AugelliAdam D’Augelli
zonebourse.com - December 28 at 8:17 PM
Zymergen Gets OK For Asset Sales : Dramatic Bankruptcy BattleZymergen Gets OK For Asset Sales : Dramatic Bankruptcy Battle
usaherald.com - December 19 at 6:56 PM
Ginkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial ResultsGinkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial Results
finance.yahoo.com - November 8 at 7:28 PM
Tech and biotech firms slash hundreds of Bay Area jobs as layoffs widenTech and biotech firms slash hundreds of Bay Area jobs as layoffs widen
msn.com - November 8 at 7:28 PM
Ginkgo Bioworks Holdings Q3 2023 Earnings PreviewGinkgo Bioworks Holdings Q3 2023 Earnings Preview
msn.com - November 7 at 2:39 PM
Gingko Bioworks, Penn State partner on wildlife biothreat researchGingko Bioworks, Penn State partner on wildlife biothreat research
msn.com - October 24 at 8:19 PM
Ginkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcyGinkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcy
msn.com - October 4 at 5:34 PM
Analyst Cautions on Ginkgo Bioworks’ Financial Prospects Despite Promising Collaborations and Sector PositionAnalyst Cautions on Ginkgo Bioworks’ Financial Prospects Despite Promising Collaborations and Sector Position
markets.businessinsider.com - October 4 at 7:33 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anavex Life Sciences logo

Anavex Life Sciences

NASDAQ:AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Medpace logo

Medpace

NASDAQ:MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
National Research logo

National Research

NASDAQ:NRC
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Syneos Health logo

Syneos Health

NASDAQ:SYNH
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
Zymergen logo

Zymergen

NASDAQ:ZY
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.